Search research articles
Contact Us
Filters
Showing results (501-510 of 564) with videos related to
Page
of 57
Sort By:
European Urology
|
January 19, 2021
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial
Robert J Motzer, Paul Russo, Naomi Haas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 8, 2014
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel
John M Fitzpatrick, Joaquim Bellmunt, Karim Fizazi, et al.
The Prostate
|
November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer
Christopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
JAMA Oncology
|
August 26, 2016
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study
Ellen S de Morrée, Nicholas J Vogelzang, Daniel P Petrylak, et al.
British Journal of Cancer
|
September 30, 2023
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database
Jakob Lauritsen, Nicolas Sauvé, Alexey Tryakin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2022
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA Expression
Cora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, et al.
BJU International
|
November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma
Gregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.
Future Oncology (London, England)
|
April 13, 2022
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
Thomas Powles, Se Hoon Park, Eric Voog, et al.
The New England Journal of Medicine
|
August 23, 2013
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
Robert J Motzer, Thomas E Hutson, David Cella, et al.
The Journal of Urology
|
November 30, 2014
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma
Roberto Iacovelli, Alessio Farcomeni, Cora N Sternberg, et al.
Page
of 57
Search research articles
Search
Showing results (501-510 of 564) with videos related to
Sort By:
Page
of 57
European Urology
|
January 19, 2021
Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial
Robert J Motzer, Paul Russo, Naomi Haas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 8, 2014
Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel
John M Fitzpatrick, Joaquim Bellmunt, Karim Fizazi, et al.
The Prostate
|
November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer
Christopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
JAMA Oncology
|
August 26, 2016
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study
Ellen S de Morrée, Nicholas J Vogelzang, Daniel P Petrylak, et al.
British Journal of Cancer
|
September 30, 2023
Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database
Jakob Lauritsen, Nicolas Sauvé, Alexey Tryakin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2022
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on <i>FGFR1</i>/<i>3</i> mRNA Expression
Cora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, et al.
BJU International
|
November 14, 2013
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma
Gregory R Pond, Neeraj Agarwal, Joaquim Bellmunt, et al.
Future Oncology (London, England)
|
April 13, 2022
Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer
Thomas Powles, Se Hoon Park, Eric Voog, et al.
The New England Journal of Medicine
|
August 23, 2013
Pazopanib versus sunitinib in metastatic renal-cell carcinoma
Robert J Motzer, Thomas E Hutson, David Cella, et al.
The Journal of Urology
|
November 30, 2014
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma
Roberto Iacovelli, Alessio Farcomeni, Cora N Sternberg, et al.
Page
of 57